官方服务：
资源简介：
Patient-level clinical drug trial data for treatment of facial paralysis
用于治疗面神经麻痹（facial paralysis）的患者水平（Patient-level）药物临床试验数据
应用场景：
创建时间：
2023-08-26
相关数据集
Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration
JX11502MA is a potent partial agonist of dopamine D2 and D3 receptors, with a preferential binding profile for D3 receptors in vitro, potentially for treating schizophrenia. A first-in-human, randomiz
DataCite Commons2024-02-12 更新190
Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial
Background: Like other alpha-2-adrenergic receptor agonists, dexmedetomidine may reduce the severity of opioid withdrawal but with fewer adverse cardiovascular effects. Objective: This study assessed
NIAID Data Ecosystem20
Additional file 2 of Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial
Additional file 2: Supplementary data.
NIAID Data Ecosystem20
Table 1_Characteristics of pediatric interventional drug trials registered between 2015 and 2024 on ClinicalTrials.gov.xlsx
AimThis study comprehensively analyzed the characteristics and development trends of pediatric interventional drug clinical trials registered between 2015 and 2024, with a focus on pharmaceutical char
NIAID Data Ecosystem30
Effect of Roflumilast 500 μg Tablets Once Daily at Acute COPD Exacerbations Treated With Standard Therapy of Oral Steroids and Antibiotics. A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). In addition, the potential
DataCite Commons2024-12-02 更新20
